Search Results
Your search for The,The matches 36179 pages
Showing 1 - 50
Yuji Shibata, MD, PhD, on HER2-Mutant NSCLC: Mechanisms of Zongertinib Resistance
Yuji Shibata, MD, PhD, of The University of Texas MD Anderson Cancer Center, describes findings on the identification of novel HER2 mutations that mediate resistance to the tyrosine kinase inhibitor zongertinib among patients with non–small cell lung cancer (NSCLC); these data also indicated that...
Lyudmila A. Bazhenova, MD, on ROS1-Positive NSCLC: Taletrectinib in TKI-Naive Patients
Lyudmila A. Bazhenova, MD, of the University of California, San Diego, presents updated data from the phase II TRUST-I and TRUST-II trials. With approximately 3 years of follow-up in the pooled analysis, investigators now conclude that the next-generation, selective ROS1 tyrosine kinase inhibitor...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
First-Line Zongertinib in Advanced HER2-Mutant NSCLC
In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC). As noted by the investigators, zongertinib is an oral, irreversible tyrosine...
Pretreatment MRI Prognostic Information After Radical Prostatectomy
In a systematic review and meta-analysis reported in JAMA Oncology, Agrotis et al found that pretreatment MRI provided important prognostic information after radical prostatectomy in patients with prostate cancer. Study Details A literature review was conducted through March 2025. Studies were...
Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252). Although it’s known that...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
Injecting the PD-1 inhibitor nivolumab directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial (ClinicalTrials.gov identifier NCT05327270) presented at the American Association for Cancer ...
Fabrice Barlesi, MD, PhD, on Resectable NSCLC: IPH5201 Plus Durvalumab and Platinum-Based Chemotherapy
Fabrice Barlesi, MD, PhD, of Gustave Roussy, discusses interim results from the phase II MATISSE trial, which looked at dual CD39 and PD-L1 inhibition in patients with resectable non–small cell lung cancer (NSCLC). The study investigated the combination of IPH5201, an investigational anti-CD39...
Manale El Kharbili, PhD, on a Novel Strategy to Eliminate MRD in HER2-Mutant NSCLC
Manale El Kharbili, PhD, of the University of Colorado Anschutz Medical Campus, discusses preclinical work that showed HER2-mutant non–small cell lung cancer (NSCLC) cell lines retained demonstrated dynamic changes in cell surface protein expression in treatment-naive vs zongertinib-induced...
Methylation-Based AI Model Classifies Tumors of Unknown Origin
An artificial intelligence (AI) model using DNA methylation patterns was able to classify tumors of unknown origin with high accuracy, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 3869). “One of the most...
Metastatic NSCLC: Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non–small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual ...
Initial Data Shows Safety for WEE1/PKMYT1 Inhibitor Combination in Advanced Solid Tumors
Initial data from the phase I study of WEE1 inhibitor zedoresertib and PKMYT1 inhibitor lunresertib demonstrated an expected and manageable safety profile in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A gene alterations, according to findings from the MYTHIC trial...
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel led to a 100% measurable residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the...
Jonathan Riess, MD, on Zoldonrasib in Previously Treated Patients With KRAS G12D–Mutant NSCLC
Jonathan Riess, MD, of the University of California, Davis, describes preliminary data on the safety and clinical activity of zoldonrasib (also known as RMC-9805), an oral, RAS(ON) G12D–selective, tricomplex inhibitor, in previously treated patients with KRAS G12D–mutant non–small cell lung cancer...
Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC
Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C inhibitor or not, according to findings from an ongoing phase I/II clinical trial presented at the ...
Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an...
Thi Van Trinh Tran, PhD, on the Histopathology of Lung Cancer in Neversmokers
Thi Van Trinh Tran, PhD, of the National Cancer Institute, describes histologic and prognostic findings from the largest cohort of lung cancer in people who have never smoked. Tumor-infiltrating lymphocyte data also reflected refined risk stratification (Abstract 1302).
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
As reported in JAMA Oncology by Richardson et al, a secondary analysis of the GAP70+ trial showed that treatment modifications and outcomes did not differ between older patients with advanced cancer who prioritized quality of life (QOL) vs those who preferred prolonging survival. Study Details This ...
ASCO Expands TAPUR Trial With Two New Precision Drug Arms
ASCO has expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) study with two new developments: The study added its first antibody-drug conjugate (ADC), fam-trastuzumab deruxtecan-nxki (T-DXd), to determine if a wider group of patients would benefit from this medicine....
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
Melanoma: Can AI Enable Diagnosis Prediction?
Assessment of machine-learning models tested on Swedish registry data enabled more accurate melanoma diagnosis prediction, with added health-care code, age, sex, and medication information for improved performance, according to the results of a study published in Acta Dermato-Venereologica. “Our...
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
Researchers have developed an artificial intelligence (AI) tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers scientists a clearer path to designing targeted therapies by showing which cells inside a tumor are most strongly...
DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors
A large prospective evaluation of off-label targeted cancer therapies has shown that more patients could potentially benefit from existing drugs. After including over 1,600 patients in the Dutch multicenter Drug Rediscovery Protocol (DRUP) trial (ClinicalTrials.gov identifier NCT02925234), the...
Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma
A population of patients with highly refractory follicular lymphoma achieved long-standing responses with few significant adverse events from odronextamab monotherapy, according to findings of the ELM-2 study. The study outcomes were published by Tessoulin et al in Clinical Lymphoma, Myeloma &...
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
In a Chinese cohort study (OCEANUS) reported in JAMA Oncology, Zhou et al found that sequential radiotherapy (RT) and immune checkpoint inhibitor (ICI) therapy was associated with better overall survival vs concurrent RT and ICI therapy in patients with advanced newly diagnosed or refractory...
Romiplostim for Chemotherapy-Induced Thrombocytopenia
In a phase III trial (RECITE) reported in The New England Journal of Medicine, Al-Samkari et al found that the thrombopoietin receptor agonist romiplostim was effective in treating chemotherapy-induced thrombocytopenia (CIT) among patients receiving oxaliplatin-based multiagent cytotoxic...
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
About one in six survivors of an adolescent and young adult cancer will develop a subsequent primary neoplasm within 30 years of their original diagnosis, according to the results of a population-based study published in the Canadian Medical Association Journal. “When combined with the relatively...
ASH/ISTH Create Guidelines for Pediatric VTE Prophylaxis
The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have released a set of comprehensive clinical practice guidelines for the use of anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. The guidelines were...
Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers
Occupational exposure to asbestos-free talc did not increase the risk for lung, mesothelioma, or laryngeal cancers, according to the results of a systemic review and meta-analysis published in the Journal of Thoracic Oncology. The study authors, including corresponding author and lead researcher...
LuPSMA-617 and Pembrolizumab in mCRPC
In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab showed “encouraging” activity in patients with metastatic castration-resistant prostate cancer (mCRPC). As stated ...
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. Several weeks ago, when the PA’s fingers moved over the mass visibly protruding...
New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia
As reported in the Journal of Clinical Oncology, Lanino et al have developed a new model (international chronic myelomonocytic leukemia [CMML] prognostic scoring system [iCPSS]) for characterizing CMML by combining molecular information with clinical information. Study Details The study involved...
Case 3: Distal Esophageal HER2-Positive Adenocarcinoma
This is Part 3 of From Diagnosis to Durability: Elevating Outcomes in Gastroesophageal Adenocarcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Yelena Janjigian, Daniela Molena, and Steven Maron discuss the nonoperative...
Case 2: Oligometastatic Gastric Adenocarcinoma
This is Part 2 of From Diagnosis to Durability: Elevating Outcomes in Gastroesophageal Adenocarcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Yelena Janjigian, Daniela Molena, and Steven Maron discuss the management...
Case 1: Locally Advanced GEJ Adenocarcinoma
This is Part 1 of From Diagnosis to Durability: Elevating Outcomes in Gastroesophageal Adenocarcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Yelena Janjigian, Daniela Molena, and Steven Maron discuss the perioperative ...
Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden
Large language models performed better than physicians at producing accurate and comprehensive oncology pathology report summaries, according to the results of a study published in JCO Clinical Cancer Informatics. Six large language models were tested in the study, and most generated summaries...
Nancy L. Lewis, MD, MBS, FACP, Named NCCN’s New Chief Scientific Officer
The National Comprehensive Cancer Network® (NCCN®) has announced the selection of Nancy L. Lewis, MD, MBS, FACP, as its new Chief Scientific Officer (CSO). Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies....
Global Survival Index for Childhood Cancer: CONCORD-4
As reported in The Lancet, Allemani et al identified findings in the CONCORD-4 study indicating the degree of progress towards the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) target of 60% 5-year survival for all childhood cancers combined by the year 2030. Study...
Can Saying ‘I Do’ Reduce Cancer Risk?
A U.S. population-based study across demographic groups and cancer types found that ever-married adults consistently had a lower cancer risk compared with never-married individuals. Published in Cancer Research Communications, these findings suggest that marital status may serve as a valuable...
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
James P. Allison, PhD, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to James P. Allison, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2026, to be held April 17-22 in San Diego. Dr. Allison is the Regental Professor and ...
Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients
In a UK retrospective cohort study reported in The Lancet Oncology, Whitworth et al analyzed the frequency of germline genetic variants in patients with cancer in the 100,000 Genomes Project. Study Details The study included data from 14,765 individuals with cancer entered into the 100,000 Genomes...
Electroacupuncture May Relieve Cognitive, Psychological Symptoms in Breast Cancer Survivors in Pilot Study
Electroacupuncture may alleviate some persistent neuropsychiatric symptoms experienced by breast cancer survivors, including psychological distress and cognitive impairment, according to the results of a randomized, double-blinded pilot trial published in the Journal of the National Cancer...
Antoni Ribas, MD, PhD, Honored With the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will present the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research to Antoni Ribas, MD, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2026, to be held April 17 to 22 in San Diego. Dr. ...
Case 3: Metastatic RCC With Symptomatic Progression After IO/IO
This is Part 3 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of metastatic renal cell...
Case 2: Advanced RCC With Mild Disease Progression After IO/IO
This is Part 2 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of advanced renal cell...
Case 1: RCC With Disease Progression After Adjuvant Pembrolizumab
This is Part 1 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of renal cell carcinoma...
Colorectal Cancer: Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy
The antidepressant duloxetine was unable to prevent sensory oxaliplatin-induced peripheral neuropathy more significantly than placebo in patients with colorectal cancer receiving chemotherapy, according to the results of the Alliance A221805 trial published in JCO Oncology Advances. “Since we know ...
American Cancer Society Announces New Pediatric, Adolescent, and Young Adult Cancer Journal
The American Cancer Society (ACS) has announced the launch of its fourth medical journal, Pediatric, Adolescent & Young Adult Cancer. This international, multidisciplinary publication will feature peer-reviewed original research and solicited content on the latest advances in cancers affecting...
Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen...
